Canaccord analyst William Plovanic raised the firm’s price target on DexCom (DXCM) to $103 from $99 and keeps a Buy rating on the shares. The firm said both US and OUS revenues were ahead of estimates from prior to the preannouncement, with US revenue growing as the company’s realigned salesforce continues to improve its productivity following the turmoil of the Q2/24 miss.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: